=> FILE REG
FILE 'REGISTRY' ENTERED AT 18:31:38 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 NOV 2009 HIGHEST RN 1192927-49-3
DICTIONARY FILE UPDATES: 19 NOV 2009 HIGHEST RN 1192927-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading L2.str



```
chain nodes :
11  12  13  14  15  22
ring nodes :
1  2  3  4  5  6  7  8  9  10  16  17  18  19  20  21
chain bonds :
8-13  10-11  11-12  12-14  14-15  15-16  15-22
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  16-17  16-21  17-18  18-19
19-20  20-21
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  8-13  9-10  10-11  11-12  12-14
14-15  15-16  15-22  16-17  16-21  17-18  18-19  19-20  20-21


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom
22:CLASS
```

Uploading L5.str




```
chain nodes :
11  12  13  14  15  22  23  24  25  26
ring nodes :
```

```
1  2  3  4  5  6  7  8  9  10  16  17  18  19  20  21
chain bonds :
8-13  10-11  11-12  12-14  12-23  14-15  15-16  15-22  19-26  23-24  23-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  16-17  16-21  17-18  18-19
19-20  20-21
exact/norm bonds :
5-7  6-10  7-8  8-9  8-13  9-10  12-14  14-15  15-22  23-24  23-25
exact bonds :
10-11  11-12  12-23  15-16  19-26
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom
22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS
```

Uploading L13.str




```
chain nodes :
11  12  13  14  15  22  23  24  25  26
```

ring nodes :
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21
chain bonds :
8-13 10-11 11-12 12-14 12-23 14-15 15-16 15-22 19-26 23-24 23-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21
exact/norm bonds :
5-7 6-10 7-8 8-9 8-13 9-10 12-14 14-15 15-22
exact bonds :
10-11 11-12 12-23 15-16 19-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-25

Connectivity :
12:3 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 18:31:46 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 19 Nov 2009 (20091119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free! Complete details on the

number of free displays and other databases participating in this offer appear in NEWS 10.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L30
L2 STR



Page 1-A



Page 2-A
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4

```
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS R      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
NSPEC   IS C      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS C      AT  22
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L4            99 SEA FILE=REGISTRY SSS FUL L2
L5               STR
```



Page 1-A



Page 2-A

Page 3-A
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS C	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
NSPEC	IS C	AT	24
NSPEC	IS C	AT	25
NSPEC	IS C	AT	26

```
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22 23 24 25 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L7            60 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L13              STR
```



Page 1-A



Page 2-A

Page 3-A

```
NODE ATTRIBUTES:
HCOUNT  IS M1      AT   4
HCOUNT  IS M1      AT   7
HCOUNT  IS M1      AT  14
HCOUNT  IS M1      AT  24
NSPEC   IS R       AT   1
NSPEC   IS R       AT   2
NSPEC   IS R       AT   3
NSPEC   IS R       AT   4
NSPEC   IS R       AT   5
NSPEC   IS R       AT   6
NSPEC   IS R       AT   7
NSPEC   IS R       AT   8
NSPEC   IS R       AT   9
NSPEC   IS R       AT  10
NSPEC   IS C       AT  11
NSPEC   IS C       AT  12
NSPEC   IS C       AT  13
NSPEC   IS C       AT  14
NSPEC   IS C       AT  15
NSPEC   IS R       AT  16
NSPEC   IS R       AT  17
NSPEC   IS R       AT  18
NSPEC   IS R       AT  19
NSPEC   IS R       AT  20
NSPEC   IS R       AT  21
NSPEC   IS C       AT  22
NSPEC   IS C       AT  23
NSPEC   IS C       AT  24
NSPEC   IS C       AT  25
NSPEC   IS C       AT  26
CONNECT IS E3  RC AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22 23 24 25 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L14          35 SEA FILE=REGISTRY SUB=L7 SSS FUL L13
L15         356 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L14
L16       57021 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  SALIVA+PFT/CT OR
                SALIVA?/BI
L17          11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L16(L)ACCELERATION/OBI

L18           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L17
L19         630 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA+OLD,PFT/CT

L20           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L19
```

```
L23          112 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L24           78 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L25         1964 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L26            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L16
L27            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18 OR L20 OR L26
L28            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L27 AND ((L23 OR L24
                  OR L25))
L29            1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L23 AND L24 AND L25
L30            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L28 OR L29


=> FILE MEDLINE
FILE 'MEDLINE' ENTERED AT 18:32:00 ON 20 NOV 2009

 FILE LAST UPDATED: 18 Nov 2009 (20091118/UP).  FILE COVERS 1949 TO DATE.

 MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject
 Headings (MeSH) vocabulary and tree numbers from the U.S.  National Library
 of Medicine (NLM).  Additional information is available at

 http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html.

 On February 21, 2009, MEDLINE was reloaded.  See HELP RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 See HELP RANGE before carrying out any RANGE search.

=> D STAT QUE L50
L21            1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                   ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L31                SEL  PLU=ON  L21 1- NAME :          4 TERMS
L32          228 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L31
L33          228 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L21 OR L32
L34        26444 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  SALIVA/CT
L37         3041 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L40            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L37
L41            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L34
L42            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L40 OR L41
L43         8594 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  "SJOGREN'S SYNDROME"/C
                   T
L44            3 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L43
L45            3 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L42 OR L44
L46           34 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L47           19 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L48          932 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L50            2 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L45 AND ((L46 OR L47
                  OR L48))


=> FILE WPIX BIOSIS
FILE 'WPIX' ENTERED AT 18:32:54 ON 20 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 18:32:54 ON 20 NOV 2009
Copyright (c) 2009 The Thomson Corporation

=> D STAT QUE L67
L64           82 SEA NAGAMOTO H?/AU
```

```
L65           73 SEA KOHASHI M?/AU
L66         3368 SEA OKA H?/AU
L67            1 SEA L64 AND L65 AND L66


=> FILE EMBASE
FILE 'EMBASE' ENTERED AT 18:33:02 ON 20 NOV 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 20 Nov 2009 (20091120/ED)

 EMBASE was reloaded on March 30, 2008.

 EMBASE is now updated daily.  SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 Beginning January 2008, Elsevier will no longer provide EMTREE
 codes as part of the EMTREE thesaurus in EMBASE.  Please update
 your current-awareness alerts (SDIs) if they contain EMTREE
 codes.

 For further assistance, please contact your local helpdesk.

=> D STAT QUE L85
L21             1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                  ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L68               SEL  PLU=ON  L21 1- NAME :       4 TERMS
L69           381 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L68
L70           381 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L21 OR L69
L71         17167 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L72          9448 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  SJOEGREN SYNDROME/CT
L74             7 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L70 AND L71
L75            12 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L70 AND L72
L77             2 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L75 AND MANAGEMENT/TI
L78             5 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L75 NOT (EYE OR
                  RHEUMATOLOGIC)/TI
L79             7 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L77 OR L78
L80             9 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L74 OR L79
L81            35 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L82            15 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L83           863 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L85             2 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L80 AND (L81 OR L82 OR
                  L83)


=> DUP REMOVE L30 L50 L67 L85
FILE 'HCAPLUS' ENTERED AT 18:33:28 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:33:28 ON 20 NOV 2009

FILE 'WPIX' ENTERED AT 18:33:28 ON 20 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 18:33:28 ON 20 NOV 2009
```

PROCESSING COMPLETED FOR L30
PROCESSING COMPLETED FOR L50
PROCESSING COMPLETED FOR L67
PROCESSING COMPLETED FOR L85
L86 3 DUP REMOVE L30 L50 L67 L85 (5 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE HCAPLUS

=> D L86 IBIB ABS HITSTR 1-3

L86 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2009:392963 HCAPLUS Full-text
DOCUMENT NUMBER: 151:395986
TITLE: Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjoegren's syndrome: a double-blind placebo-controlled multicenter trial
AUTHOR(S): Sugai, Susumu; Takahashi, Hiroki; Ohta, Shuji; Nishinarita, Makoto; Takei, Masami; Sawada, Shigemasa; Yamaji, Ken; Oka, Hiroshi; Umehara, Hisanori; Koni, Ichiro; Sugiyama, Eiji; Nishiyama, Susumu; Kawakami, Atsushi
CORPORATE SOURCE: Kanazawa Medical University, Ishikawa, Japan
SOURCE: Modern Rheumatology (2009), 19(2), 114-124
CODEN: MROHA4; ISSN: 1439-7595
PUBLISHER: Springer Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of rebamipide on dry mouth and salivary secretion in Sjoegren's syndrome patients were investigated in a double-blind placebo-controlled study. Rebamipide (100 mg TID) or placebo was administered for eight weeks and patient-assessed improvement of dry mouth and increase in salivary secretion measured by the Saxon test were evaluated. At two, four, and eight weeks, dry mouth improvement rates were, resp., 26.0%, 44.0%, and 46.9% for rebamipide and 20.0%, 27.1%, and 39.1% for placebo, and mean increases in salivary secretion were, resp., 0.14, 0.24, and 0.35 g for rebamipide and 0.03, 0.09, and 0.17 g for placebo, indicating higher values in the rebamipide group for both parameters at all timepoints but no significant differences between the two groups. Anal. by baseline characteristics suggested a statistically significant salivary secretion increasing effect of rebamipide in cases of primary Sjoegren's syndrome. No difference in the incidence of adverse events was seen between the two groups, confirming the safety of rebamipide. As a salivary secretion increasing effect was strongly suggested in cases of primary Sjoegren's syndrome, further study on the administration of rebamipide for the treatment of dry mouth in patients with Sjoegren's syndrome is required.

IT 90098-04-7, Mucosta
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mucosta was effective in increasing salivary secretion but had no effect on dry mouth symptoms in patient with Sjogren's syndrome)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2008:292244 HCAPLUS Full-text
DOCUMENT NUMBER: 148:576370
TITLE: Effective treatment with oral administration of rebamipide in a mouse model of Sjogren's syndrome
AUTHOR(S): Kohashi, Masayuki; Ishimaru, Naozumi; Arakaki, Rieko; Hayashi, Yoshio
CORPORATE SOURCE: University of Tokushima Graduate School, Tokushima, Japan
SOURCE: Arthritis & Rheumatism (2008), 58(2), 389-400 CODEN: ARHEAW; ISSN: 0004-3591
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: To determine whether oral administration of rebamipide, a mucosal protective agent, is effective in the treatment of Sjogren's syndrome (SS) in the NFS/sld mouse model of the disease. Methods: NFS/sld mice were given daily oral doses of rebamipide (0.3 mg/kg of body weight or 3 mg/kg) or vehicle alone starting from the age of 4 wk to the age of 8 wk. The volume of saliva and tears was monitored during and after treatment. After the final dose, histol. features of the tissues, TUNEL + apoptotic duct cells in affected glands, T cell and cytokine function, and levels of Ig isotypes and serum autoantibodies were examined Results: The 3-mg/kg dose of rebamipide prevented the development of autoimmune lesions. The average volume of saliva in rebamipide-treated mice was significantly higher than that in control mice. We found decreased TUNEL + apoptotic duct cells in the salivary and lacrimal glands of rebamipide-treated mice as compared with control mice. Rebamipide treatment suppressed the activation of CD4 + T cells and Th1 cytokines (interleukin-2, interferon-γ) associated with impaired NF-κB activity. Production of serum autoantibodies, IgM, and IgG1 was clearly inhibited. Conclusion: Our findings demonstrate the efficacy of oral administration of rebamipide in the treatment of SS. Rebamipide represents a new therapeutic strategy for the treatment of patients with sicca symptoms caused by SS, as well as for patients with other diseases.

IT 90098-04-7, Rebamipide
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effective treatment with oral administration of rebamipide in mouse model of Sjogren's syndrome)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:120780 HCAPLUS Full-text
DOCUMENT NUMBER: 142:183519
TITLE: Carbostyril derivatives for accelerating salivation
INVENTOR(S): Nagamoto, Hisashi; Kohashi, Masayuki ; Oka, Hiroshi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan; St. Marianna University School of Medicine
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011811	A1	20050210	WO 2004-JP9992	20040707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1648563	A1	20060426	EP 2004-747458	20040707
EP 1648563	B1	20070919		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

CN 1859948	A	20061108	CN 2004-80027975		20040707
JP 2006528662	T	20061221	JP 2006-521775		20040707
AT 373502	T	20071015	AT 2004-747458		20040707
KR 2006037408	A	20060503	KR 2006-701933		20060127
US 20070112026	A1	20070517	US 2006-566214		20060127
PRIORITY APPLN. INFO.:			JP 2003-282691	A	20030730
			JP 2004-21808	A	20040129
			WO 2004-JP9992	W	20040707

OTHER SOURCE(S): MARPAT 142:183519

AB An oral pharmaceutical composition for accelerating salivation and prophylaxis and/or treatment of xerostomia or hyposalivation comprises as an active ingredient a carbostyril compound or a pharmaceutically acceptable salt thereof. For example, a mixture containing 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid (Rebamipide) 150 g, Avicel 40 g, corn starch 30 g, and magnesium stearate 2 g was tableted and film coated with a composition containing hydroxypropyl Me cellulose 10 g, polyethylene glycol 6000 3 g, castor oil 40 g, and methanol 40 g. Tablets containing 100 mg Rebamipide per tablet were orally administered three times per day immediately after a meal to patients having Sjogren's syndrome. An increase of salivation was observed with the effectiveness of 52.4% after 4 wk and 61.9% after 8 wk of administration.

IT 90098-04-7, Rebamipide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral carbostyril derivs. for accelerating salivation)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 18:33:53 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 19 Nov 2009 (20091119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free! Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L53
L2 STR



Page 1-A



Page 2-A
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10

```
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
NSPEC   IS C      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS C      AT  22
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L4            99 SEA FILE=REGISTRY SSS FUL L2
L5               STR
```



Page 1-A



Page 2-A

Page 3-A
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS C	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
NSPEC	IS C	AT	24
NSPEC	IS C	AT	25
NSPEC	IS C	AT	26

```
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22 23 24 25 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L7            60 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L13              STR
```



Page 1-A



Page 2-A

```
C1 26
```

Page 3-A

```
NODE ATTRIBUTES:
HCOUNT  IS M1      AT   4
HCOUNT  IS M1      AT   7
HCOUNT  IS M1      AT  14
HCOUNT  IS M1      AT  24
NSPEC   IS R       AT   1
NSPEC   IS R       AT   2
NSPEC   IS R       AT   3
NSPEC   IS R       AT   4
NSPEC   IS R       AT   5
NSPEC   IS R       AT   6
NSPEC   IS R       AT   7
NSPEC   IS R       AT   8
NSPEC   IS R       AT   9
NSPEC   IS R       AT  10
NSPEC   IS C       AT  11
NSPEC   IS C       AT  12
NSPEC   IS C       AT  13
NSPEC   IS C       AT  14
NSPEC   IS C       AT  15
NSPEC   IS R       AT  16
NSPEC   IS R       AT  17
NSPEC   IS R       AT  18
NSPEC   IS R       AT  19
NSPEC   IS R       AT  20
NSPEC   IS R       AT  21
NSPEC   IS C       AT  22
NSPEC   IS C       AT  23
NSPEC   IS C       AT  24
NSPEC   IS C       AT  25
NSPEC   IS C       AT  26
CONNECT IS E3  RC AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 15 22 23 24 25 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L14          35 SEA FILE=REGISTRY SUB=L7 SSS FUL L13
L15         356 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L14
L16       57021 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  SALIVA+PFT/CT OR
                SALIVA?/BI
L17          11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L16(L)ACCELERATION/OBI

L18           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L17
L19         630 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA+OLD,PFT/CT

L20           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L19
```

```
L26             3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L16
L27             3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18 OR L20 OR L26
L51          3703 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  SJOGREN SYNDROME+OLD,P
                  FT/CT
L52             4 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND L51
L53             4 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L27 OR L52


=> FILE MEDLINE
FILE 'MEDLINE' ENTERED AT 18:34:11 ON 20 NOV 2009

 FILE LAST UPDATED: 18 Nov 2009 (20091118/UP).  FILE COVERS 1949 TO DATE.

 MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject
 Headings (MeSH) vocabulary and tree numbers from the U.S.  National Library
 of Medicine (NLM).  Additional information is available at

 http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html.

 On February 21, 2009, MEDLINE was reloaded.  See HELP RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 See HELP RANGE before carrying out any RANGE search.

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 18:34:19 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Nov 2009  VOL 151 ISS 22
FILE LAST UPDATED: 19 Nov 2009  (20091119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
```

```
offer appear in NEWS 10.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> S L53 NOT L30
L87          1 L53 NOT L30

=> FILE MEDLINE
FILE 'MEDLINE' ENTERED AT 18:34:42 ON 20 NOV 2009

 FILE LAST UPDATED: 18 Nov 2009 (20091118/UP).  FILE COVERS 1949 TO DATE.

 MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject
 Headings (MeSH) vocabulary and tree numbers from the U.S.  National Library
 of Medicine (NLM).  Additional information is available at

 http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html.

 On February 21, 2009, MEDLINE was reloaded.  See HELP RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 See HELP RANGE before carrying out any RANGE search.

=> D STAT QUE L45
L21            1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                   ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L31               SEL  PLU=ON  L21 1- NAME :       4 TERMS
L32          228 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L31
L33          228 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L21 OR L32
L34        26444 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  SALIVA/CT
L37         3041 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L40            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L37
L41            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L34
L42            1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L40 OR L41
L43         8594 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  "SJOGREN'S SYNDROME"/C
                   T
L44            3 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L33 AND L43
L45            3 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L42 OR L44


=> S L45 NOT L50
L88          1 L45 NOT L50

=> FILE WPIX BIOSIS
FILE 'WPIX' ENTERED AT 18:35:23 ON 20 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 18:35:23 ON 20 NOV 2009
Copyright (c) 2009 The Thomson Corporation

=> D STAT QUE L60
L21            1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                   ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L54               SEL  PLU=ON  L21 1- NAME :       4 TERMS
L55          379 SEA L54
L56          379 SEA L21 OR L55
L57         3824 SEA SALIVA?(10A)(ACCEL? OR INCREAS?)
L60            0 SEA L56(30A) L57
```

```
=> D STAT QUE L62
L21             1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                  ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L54               SEL  PLU=ON  L21 1- NAME :       4 TERMS
L55           379 SEA L54
L56           379 SEA L21 OR L55
L61          4470 SEA XEROSTO? OR DRY(3A) MOUTH?
L62             0 SEA L56 AND L61


=> FILE EMBASE
FILE 'EMBASE' ENTERED AT 18:35:44 ON 20 NOV 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 20 Nov 2009 (20091120/ED)

 EMBASE was reloaded on March 30, 2008.

 EMBASE is now updated daily.  SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 Beginning January 2008, Elsevier will no longer provide EMTREE
 codes as part of the EMTREE thesaurus in EMBASE.  Please update
 your current-awareness alerts (SDIs) if they contain EMTREE
 codes.

 For further assistance, please contact your local helpdesk.

=> D STAT QUE L80
L21             1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC
                  ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN
L68               SEL  PLU=ON  L21 1- NAME :       4 TERMS
L69           381 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L68
L70           381 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L21 OR L69
L71         17167 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L72          9448 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  SJOEGREN SYNDROME/CT
L74             7 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L70 AND L71
L75            12 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L70 AND L72
L77             2 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L75 AND MANAGEMENT/TI
L78             5 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L75 NOT (EYE OR
                  RHEUMATOLOGIC)/TI
L79             7 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L77 OR L78
L80             9 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L74 OR L79


=> S L80 NOT L85
L89             7 L80 NOT L85

=> DUP REMOVE L87 L88 L89
FILE 'HCAPLUS' ENTERED AT 18:36:18 ON 20 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:36:18 ON 20 NOV 2009
```

```
FILE 'EMBASE' ENTERED AT 18:36:18 ON 20 NOV 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.
PROCESSING COMPLETED FOR L87
PROCESSING COMPLETED FOR L88
PROCESSING COMPLETED FOR L89
L90             8 DUP REMOVE L87 L88 L89 (1 DUPLICATE REMOVED)
                  ANSWER '1' FROM FILE HCAPLUS
                  ANSWER '2' FROM FILE MEDLINE
                  ANSWERS '3-8' FROM FILE EMBASE


L90  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:1267017  HCAPLUS  Full-text
DOCUMENT NUMBER:          151:478529
TITLE:                    Topical LFA-1 antagonists for use in localized
                          treatment of immune related disorders
INVENTOR(S):              Burnier, John; Gadek, Thomas
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 85pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    -------------------    --------
     US 20090258070       A1    20091015    US 2009-386359         20090415
     WO 2009128934        A1    20091022    WO 2009-US2389         20090415
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                        US 2008-45240P      P  20080415
AB    This invention provides specifically formulated LFA-1 antagonists or
      pharmaceutically acceptable salts thereof that are suitable for topical delivery.
      In particular, the LFA-1 antagonists are particularly well suited for localized
      treatment by having a rapid systemic clearance rate. The invention also encompasses
      methods of treatment and prevention of immune related disorders using the LFA-1
      topical formulations of the present invention.
INCL  424489000; 514314000; 514311000; 514300000; 514448000; 514009000
CC    63-6 (Pharmaceuticals)
      Section cross-reference(s): 1
IT    Alopecia
      Angiogenesis inhibitors
      Anti-inflammatory agents
      Antiarthritics
      Antiasthmatics
      Antimicrobial agents
      Antioxidants
      Antirheumatic agents
      Antiulcer agents
      Antiviral agents
```

Arthralgia
Asthma
Beeswax
Blood plasma
Chelating agents
Chronic obstructive pulmonary disease
Complexing agents
Crohn disease
Eczema
Edema
Emulsions
Graves' disease
Human
Immune disease
Immunomodulators
Lubricants
Oral drug delivery systems
Permeation enhancers
Pharmaceutical creams
Pharmaceutical emulsions
Pharmaceutical foams
Pharmaceutical gels
Pharmaceutical ointments
Pharmaceutical pastes
Pharmaceutical powders
Pharmaceutical solutions
Pharmaceutical sprays
Pharmaceutical suspensions
Psoriasis
Pulmonary fibrosis
Retinal disease
Retinitis
Rheumatoid arthritis
Sjogren syndrome
Surfactants
T cell
Topical drug delivery systems
Ulcerative colitis
Uveitis
Volatile substances
Wetting agents
(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

IT 59865-13-3, Cyclosporine 59985-21-6, Diquafosol 90098-04-7, Rebamipide 245466-70-0 851784-48-0 851784-50-4 851784-54-8 851784-56-0 851784-64-0 851784-72-0 915397-46-5 915397-52-3 915397-63-6 915397-90-9 915397-99-8 1025967-78-5 1026240-04-9 1148048-06-9 1148048-11-6 1148048-14-9 1148048-17-2 1148048-24-1 1148048-27-4 1148048-29-6 1148048-36-5 1148048-38-7
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

IT 90098-04-7, Rebamipide
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-

oxo- (CA INDEX NAME)



L90 ANSWER 2 OF 8 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2009123510 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 18841440
TITLE: Sjogren's syndrome: promising, new treatment options besides nizatidine.
AUTHOR: Kapoor Shailendra
SOURCE: Modern rheumatology / the Japan Rheumatism Association, (2009) Vol. 19, No. 1, pp. 100-1. Electronic Publication: 2008-10-08.
Journal code: 100959226. ISSN: 1439-7595.
COMMENT: Comment on: Mod Rheumatol. 2008;18(5):455-9. PubMed ID: 18478182
PUB. COUNTRY: Japan
DOCUMENT TYPE: Commentary
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200906
ENTRY DATE: Entered STN: 10 Feb 2009
Last Updated on STN: 2 Jul 2009
Entered Medline: 30 Jun 2009
CONTROLLED TERM: *Alanine: AA, analogs & derivatives
Alanine: TU, therapeutic use
Antioxidants: TU, therapeutic use
*Flax
Histamine H2 Antagonists: TU, therapeutic use
Humans
*Nizatidine: TU, therapeutic use
*Plant Preparations: TU, therapeutic use
*Quinolones: TU, therapeutic use
*Seeds
*Sjogren's Syndrome: DT, drug therapy
Treatment Outcome
CAS REGISTRY NO.: 111911-97-6 (rebamipide); 56-41-7 (Alanine); 76963-41-2 (Nizatidine)
CHEMICAL NAME: 0 (Antioxidants); 0 (Histamine H2 Antagonists); 0 (Plant

Preparations); 0 (Quinolones)

L90 ANSWER 3 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2008439484 EMBASE Full-text
TITLE: Rebamipide as an important adjunctive tool in the management of rheumatologic disorders: Comment on the article by Kohashi et al.
AUTHOR: Kapoor, Shailendra, Dr. (correspondence)
CORPORATE SOURCE: University of Illinois at Chicago.
SOURCE: Arthritis and Rheumatism, (September 2008) Vol. 58, No. 9, pp. 2923.
Refs: 9
ISSN: 0004-3591 CODEN: ARHEAW
PUBLISHER: John Wiley and Sons Inc., P.O.Box 18667, Newark, NJ 07191-8667, United States.
COUNTRY: United States
DOCUMENT TYPE: Journal; Letter
FILE SEGMENT: 031 Arthritis and Rheumatism
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Oct 2008
Last Updated on STN: 17 Oct 2008
CONTROLLED TERM: Medical Descriptors:
angiogenesis
aphthous ulcer: DT, drug therapy
Behcet disease
digestive system ulcer: DT, drug therapy
digestive system ulcer: PC, prevention
drug efficacy
human
letter
priority journal
*rheumatic disease: DT, drug therapy
Sjoegren syndrome: DT, drug therapy
ulcerative colitis: DT, drug therapy
xerostomia: DT, drug therapy
CONTROLLED TERM: Drug Descriptors:
misoprostol: CM, drug comparison
nonsteroid antiinflammatory agent
*rebamipide: CM, drug comparison
*rebamipide: DT, drug therapy
*rebamipide: PD, pharmacology
CAS REGISTRY NO.: (misoprostol) 59122-46-2, 59122-48-4; (rebamipide) 115115-87-6

L90 ANSWER 4 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2008502560 EMBASE Full-text
TITLE: Treatment of Dry Eye Disease by the Non-Ophthalmologist.
AUTHOR: Foulks, Gary N., Dr. (correspondence)
CORPORATE SOURCE: Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, 301 East Muhammad Ali Boulevard, Louisville, KY 40202, United States. gnfoul01@louisville.edu
SOURCE: Rheumatic Disease Clinics of North America, (November 2008) Vol. 34, No. 4, pp. 987-1000.
Refs: 72

ISSN: 0889-857X CODEN: RDCAEK
PUBLISHER: W.B. Saunders, Independence Square West, Philadelphia, PA 19106-3399, United States.
PUBLISHER IDENT.: S 0889-857X(08)00079-3
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 012 Ophthalmology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 3 Dec 2008
Last Updated on STN: 3 Dec 2008

ABSTRACT: Physicians caring for patients who have Sjogren's syndrome often face a particularly difficult task in managing the dry eye that occurs with this disease. The discomfort produced by the condition and the fluctuation of vision attendant to tear film instability are often the most annoying of the clinical symptoms. The understanding of dry eye disease in both its clinical expression and underlying etiopathology has expanded over the past 10 years with implications for management and therapy. The array of potential treatments both topical and systemic has evolved to provide a much more targeted and effective arsenal from which the clinician may choose. .COPYRGT. 2008 Elsevier Inc.

CONTROLLED TERM: Medical Descriptors:
antiinflammatory activity
cataract: SI, side effect
clinical trial
disease classification
disease severity
drug efficacy
*dry eye: DT, drug therapy
*dry eye: ET, etiology
*dry eye: SU, surgery
*dry eye: TH, therapy
eye inflammation: DT, drug therapy
glaucoma: SI, side effect
hormonal therapy
human
keratoconjunctivitis sicca: DT, drug therapy
lacrimation
pathogenesis
priority journal
review
rosacea: DT, drug therapy
sebaceous gland disease: DT, drug therapy
serum
Sjoegren syndrome
superinfection: SI, side effect
treatment outcome
xerostomia: DT, drug therapy
CONTROLLED TERM: Drug Descriptors:
12 sulfodehydroabietic acid: CT, clinical trial
12 sulfodehydroabietic acid: DT, drug therapy
12 sulfodehydroabietic acid: TP, topical drug administration
acetylcysteine: DT, drug therapy
acetylcysteine: TP, topical drug administration
antiinflammatory agent: DT, drug therapy
artificial tear: DT, drug therapy

artificial tear: TP, topical drug administration
cevimeline: DT, drug therapy
cevimeline: PO, oral drug administration
corticosteroid: CB, drug combination
corticosteroid: DT, drug therapy
corticosteroid: TP, topical drug administration
cyclosporin A: AE, adverse drug reaction
cyclosporin A: CB, drug combination
cyclosporin A: DT, drug therapy
cyclosporin A: PD, pharmacology
cyclosporin A: TP, topical drug administration
diquafosol: CT, clinical trial
diquafosol: DT, drug therapy
diquafosol: TP, topical drug administration
estratest: DT, drug therapy
estrogen: DT, drug therapy
estrogen: TP, topical drug administration
eye drops: DT, drug therapy
eye drops: TP, topical drug administration
idestrin estradiol
immunomodulating agent: DT, drug therapy
immunomodulating agent: TP, topical drug administration
lipid emulsion: CT, clinical trial
lipid emulsion: DT, drug therapy
lipid emulsion: TP, topical drug administration
loteprednol etabonate: DT, drug therapy
loteprednol etabonate: TP, topical drug administration
lubricating agent: CB, drug combination
lubricating agent: DT, drug therapy
lubricating agent: TP, topical drug administration
omega 3 fatty acid: CB, drug combination
omega 3 fatty acid: DT, drug therapy
omega 3 fatty acid: PO, oral drug administration
omega 3 fatty acid: TP, topical drug administration
optive
pilocarpine: CT, clinical trial
pilocarpine: DT, drug therapy
pilocarpine: PO, oral drug administration
rebamipide: CT, clinical trial
rebamipide: DT, drug therapy
rebamipide: TP, topical drug administration
refresh endura
soothe
steroid: AE, adverse drug reaction
steroid: DT, drug therapy
steroid: TP, topical drug administration
systane
testosterone: CT, clinical trial
testosterone: DT, drug therapy
testosterone: TP, topical drug administration
tetracycline: DT, drug therapy
theratears nutrition
unclassified drug

SUPPLEMENTARY TERM: Cyclosporine; Dry eye; Secretagogues; Sjogren's syndrome

CAS REGISTRY NO.: (12 sulfodehydroabietic acid) 33159-27-2, 86408-72-2; (acetylcysteine) 616-91-1; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2; (diquafosol) 211427-08-6; (loteprednol etabonate) 82034-46-6; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (rebamipide) 111911-87-6; (testosterone) 58-22-0; (tetracycline)

23843-90-5, 60-54-8, 64-75-5
CHEMICAL NAME: (1) estratest; (2) evoxac; (3) idestrin estradiol; (4) lotemax; (5) optive; (6) refresh endura; (7) restasis; (8) salagen; (9) soothe; (10) systane; (11) theratears nutrition
COMPANY NAME: (1) Solvay (United States); (2) Daiichi Seiyaku (United States); (3) nascent (United States); (4) Bausch and Lomb (United States); (5) Allergan (United States); (6) Allergan (United States); (7) Allergan (United States); (8) MGI (United States); (9) Bausch and Lomb (United States); (10) Alcon (United States); (11) advanced research (United States); Inspire (United States); Novartis (United States); Otsuka (United States)

L90 ANSWER 5 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2008312638 EMBASE Full-text
TITLE: Current and prospective treatment options for Sjogren,s syndrome.
AUTHOR: Sugai, Susumu, Dr. Prof. (correspondence)
CORPORATE SOURCE: Kudo General Hospital, Kanazawa Medical University, Kanazawa, Japan. sussugai@helen.ocn.ne.jp
AUTHOR: Masaki, Yasafumi
CORPORATE SOURCE: Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan. yasum@kanazawa-med.ac.jp
AUTHOR: Sugai, Susumu, Dr. Prof. (correspondence)
CORPORATE SOURCE: Kudo General Hospital, Kanazawa University, Kanazawa, Japan . sussugai@helen.ocn.ne.jp
SOURCE: Expert Review of Clinical Immunology, (Jul 2008) Vol. 4, No. 4, pp. 469-479.
Refs: 87
ISSN: 1744-666X
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 011 Otorhinolaryngology
012 Ophthalmology
026 Immunology, Serology and Transplantation
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 2008
Last Updated on STN: 10 Jul 2008
ABSTRACT: Sjogren's syndrome is both an organ-specific and a systemic autoimmune disease. Patients with dry eyes and dry mouth usually receive symptomatic treatment. Topical cyclosporine A may be administered to patients with dry eyes. The efficacy of muscarinic agonists, such as pilocarpine and cevimeline, in increasing salivary and lacrimal flow and improving patient symptoms has been well documented. Mild immunomodulatory or immunosuppressive medication is preferable to prevent the mild progressive course of the disorders. Other patients who show aggressive progression to organ disorders should be managed differently. High doses of corticosteroids, immunosuppressive agents or new biological agents, such as antibodies to CD20, are required for these patients. The elimination of B lymphocytes by anti-CD20 antibodies may be highly beneficial; however, the development of more selective drugs based on the pathogenesis of the disease is required for the future treatment of Sjogren's syndrome. .COPYRGT. 2008 Expert Reviews Ltd.

CONTROLLED TERM: Medical Descriptors:

abdominal pain: SI, side effect
B lymphocyte
clinical trial
disease course
drug dose comparison
drug dose increase
drug efficacy
drug induced headache: SI, side effect
drug mechanism
drug megadose
drug safety
drug selectivity
drug targeting
drug tolerability
dry eye: DT, drug therapy
dry eye: SU, surgery
human
immunopathogenesis
keratoconjunctivitis sicca: DT, drug therapy
keratoconjunctivitis sicca: SU, surgery
low drug dose
monotherapy
mucosa associated lymphoid tissue lymphoma: DT, drug therapy
nausea: SI, side effect
nonhuman
plasmapheresis
recommended drug dose
regulatory T lymphocyte
review
salivation
side effect: SI, side effect
*Sjoegren syndrome: DT, drug therapy
*Sjoegren syndrome: ET, etiology
sweating
tear flow
unspecified side effect: SI, side effect
vasculitis: DT, drug therapy
vasculitis: TH, therapy
viral gene delivery system
viral gene therapy
xerostomia: DT, drug therapy

CONTROLLED TERM: Drug Descriptors:
alpha interferon: CT, clinical trial
alpha interferon: DO, drug dose
alpha interferon: DT, drug therapy
alpha interferon: PO, oral drug administration
alpha interferon: PD, pharmacology
antirheumatic agent: DT, drug therapy
aquaporin 1: DT, drug therapy
artificial tear: DT, drug therapy
CD20 antibody: DT, drug therapy
CD40 ligand monoclonal antibody: DT, drug therapy
CD40 ligand monoclonal antibody: IP, intraperitoneal drug administration
CD40 ligand monoclonal antibody: PD, pharmacology
cevimeline: AE, adverse drug reaction
cevimeline: CT, clinical trial
cevimeline: DO, drug dose
cevimeline: DT, drug therapy
cevimeline: PO, oral drug administration

cevimeline: PD, pharmacology
corticosteroid: CB, drug combination
corticosteroid: DO, drug dose
corticosteroid: DT, drug therapy
corticosteroid: PO, oral drug administration
cyclophosphamide: CB, drug combination
cyclophosphamide: DT, drug therapy
cyclophosphamide: IV, intravenous drug administration
cyclosporin A: DT, drug therapy
cyclosporin A: TP, topical drug administration
doxorubicin: CB, drug combination
doxorubicin: DT, drug therapy
etanercept: CT, clinical trial
etanercept: DT, drug therapy
gefarnate: DT, drug therapy
gefarnate: PD, pharmacology
hydroxychloroquine: DT, drug therapy
hydroxychloroquine: PD, pharmacology
immunomodulating agent: DT, drug therapy
immunosuppressive agent: DT, drug therapy
infliximab: CT, clinical trial
infliximab: DT, drug therapy
interleukin 10: DT, drug therapy
interleukin 10: PD, pharmacology
mizoribine: AE, adverse drug reaction
mizoribine: CT, clinical trial
mizoribine: DT, drug therapy
mizoribine: PD, pharmacology
muscarinic agent: DT, drug therapy
parvovirus vector
pilocarpine: AE, adverse drug reaction
pilocarpine: CT, clinical trial
pilocarpine: DO, drug dose
pilocarpine: DT, drug therapy
pilocarpine: PO, oral drug administration
pilocarpine: PD, pharmacology
pilocarpine: SC, subcutaneous drug administration
placebo
prednisolone: DT, drug therapy
prednisone: CB, drug combination
prednisone: DT, drug therapy
rebamipide: AE, adverse drug reaction
rebamipide: CT, clinical trial
rebamipide: DT, drug therapy
rebamipide: PO, oral drug administration
rebamipide: PD, pharmacology
rituximab: CT, clinical trial
rituximab: CB, drug combination
rituximab: DO, drug dose
rituximab: DT, drug therapy
sni 2011
tumor necrosis factor alpha inhibitor: DT, drug therapy
unindexed drug
vincristine: CB, drug combination
vincristine: DT, drug therapy

CAS REGISTRY NO.: (aquaporin 1) 146410-94-8, 149348-86-7; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclophosphamide) 50-18-0; (cyclosporin A) 59865-13-3, 63798-73-2; (doxorubicin) 23214-92-8, 25316-40-9; (etanercept) 185243-69-0, 200013-86-1; (gefarnate) 51-77-4; (hydroxychloroquine) 118-42-3, 525-31-5; (infliximab)

170277-31-3; (mizoribine) 50924-49-7; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (prednisolone) 50-24-8; (prednisone) 53-03-2; (rebamipide) 111911-87-6; (rituximab) 174722-31-7; (vincristine) 57-22-7

CHEMICAL NAME: sni 2011

L90 ANSWER 6 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008131921 EMBASE Full-text

TITLE: Primary Sjogren's Syndrome: Current and Prospective Therapies.

AUTHOR: Thanou-Stavraki, Aikaterini; James, Judith A., Dr. (correspondence)

CORPORATE SOURCE: Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu

AUTHOR: Thanou-Stavraki, Aikaterini; James, Judith A., Dr. (correspondence)

CORPORATE SOURCE: Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu

AUTHOR: James, Judith A., Dr. (correspondence)

CORPORATE SOURCE: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu

SOURCE: Seminars in Arthritis and Rheumatism, (Apr 2008) Vol. 37, No. 5, pp. 273-292.
Refs: 251
ISSN: 0049-0172 CODEN: SAHRBF

PUBLISHER IDENT.: S 0049-0172(07)00113-8

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
006 Internal Medicine

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 7 Apr 2008
Last Updated on STN: 7 Apr 2008

ABSTRACT: Objective: To summarize data on existing and experimental therapies for primary Sjogren's syndrome (pSS), referring both to sicca syndrome and to other systemic disease manifestations. Methods: Relevant English and non-English articles acquired through Medline were reviewed. Results: pSS usually has a benign clinical course, centered on sicca features and general musculoskeletal manifestations, and is managed symptomatically. However, a subset of patients develops more severe extraglandular disease that warrants close monitoring and aggressive treatment. For dry eyes and mouth, nonpharmacologic measures to preserve secretions, and tear and saliva substitutes, offer some symptomatic relief. Muscarinic agonists and topical cyclosporine yield well-documented improvement in ocular sicca features. Although traditional antirheumatic drugs are used empirically for polyarthritis and other Sjogren's symptoms, their efficacy in pSS overall and as disease-modifying agents is limited. For the potential severe, nonexocrine manifestations complicating pSS, standard high-dose immunosuppression is used. Among the biologic agents already examined in pSS, those targeting tumor necrosis factor (TNF)-α failed to demonstrate significant benefit. Nonetheless, rituximab and other B-cell-depleting therapies appear promising. Conclusions: Treatment of pSS patients with severe extraglandular disease

should differ from that of patients with predominantly sicca features and/or general muscoloskeletal manifestations. pSS treatment is mainly symptomatic, primarily directed against sicca complaints. The traditional anti-rheumatic agents show limited efficacy in the systemic process and use of systemic TNF-α inhibitors has been very disappointing. B cell depleting treatments and other newer biologic therapies appear more promising.

CONTROLLED TERM: Medical Descriptors:
antiinflammatory activity
article
atopic dermatitis: DT, drug therapy
B cell lymphoma
clinical feature
clinical trial
disease severity
drug efficacy
drug indication
drug safety
dry eye: DT, drug therapy
dry eye: SI, side effect
eye discharge: DT, drug therapy
glomerulonephritis
hematologic disease
human
immunosuppressive treatment
keratoconjunctivitis sicca: SU, surgery
lacrimal gland disease: DT, drug therapy
lacrimation
low drug dose
lymphocyte depletion
MEDLINE
menopausal syndrome: DT, drug therapy
neurologic disease
patient monitoring
polyarthritis: DT, drug therapy
priority journal
salivation
*Sjoegren syndrome: DT, drug therapy
topical treatment
treatment outcome
vasculitis
viral gene delivery system
xerostomia: DT, drug therapy
xerostomia: TH, therapy

CONTROLLED TERM: Drug Descriptors:
12 sulfodehydroabietic acid: DT, drug therapy
alpha interferon: DO, drug dose
alpha interferon: DT, drug therapy
alpha interferon: PO, oral drug administration
alpha interferon: PA, parenteral drug administration
alpha interferon: PD, pharmacology
antihistaminic agent: AE, adverse drug reaction
antiinflammatory agent: DT, drug therapy
antirheumatic agent: DT, drug therapy
beta adrenergic receptor blocking agent: AE, adverse drug reaction
cevimeline: CM, drug comparison
cevimeline: DT, drug therapy
corticosteroid: DT, drug therapy

corticosteroid: TP, topical drug administration
cyclosporin A: CT, clinical trial
cyclosporin A: CR, drug concentration
cyclosporin A: DT, drug therapy
cyclosporin A: PK, pharmacokinetics
cyclosporin A: PD, pharmacology
cyclosporin A: TP, topical drug administration
diquafosol: DT, drug therapy
diquafosol: PD, pharmacology
diquafosol: TP, topical drug administration
disease modifying antirheumatic drug: DT, drug therapy
diuretic agent: AE, adverse drug reaction
estratest: DT, drug therapy
eye drops: DT, drug therapy
eye drops: TP, topical drug administration
gefarnate: DT, drug therapy
immunosuppressive agent: DT, drug therapy
muscarinic agent: DT, drug therapy
nonsteroid antiinflammatory agent: DT, drug therapy
nonsteroid antiinflammatory agent: TP, topical drug administration
pilocarpine: CM, drug comparison
pilocarpine: DT, drug therapy
pimecrolimus: DT, drug therapy
pimecrolimus: TP, topical drug administration
rebamipide: DT, drug therapy
recombinant interleukin 10: DT, drug therapy
rituximab: DT, drug therapy
tacrolimus: DT, drug therapy
tacrolimus: TP, topical drug administration
testosterone: DT, drug therapy
testosterone: TP, topical drug administration
testosterone: TD, transdermal drug administration
tricyclic antidepressant agent: AE, adverse drug reaction
tumor necrosis factor alpha: EC, endogenous compound
tumor necrosis factor alpha receptor: DT, drug therapy
unindexed drug
vasoactive intestinal polypeptide: DT, drug therapy
vasoactive intestinal polypeptide: PD, pharmacology

CAS REGISTRY NO.: (12 sulfodehydroabietic acid) 33159-27-2, 86408-72-2; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2; (diquafosol) 211427-08-6; (gefarnate) 51-77-4; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (pimecrolimus) 137071-32-0; (rebamipide) 111911-87-6; (rituximab) 174722-31-7; (tacrolimus) 104987-11-3; (testosterone) 58-22-0; (vasoactive intestinal polypeptide) 37221-79-7

CHEMICAL NAME: (1) evoxac; (2) restasis; (3) salagen; evoxac

COMPANY NAME: (1) Daiichi Seiyaku (United States); (2) Allergan (United States); (3) Novartis (United States)

L90 ANSWER 7 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008073013 EMBASE Full-text

TITLE: Pharmacological management of dry eye in the elderly patient.

AUTHOR: Foulks, Gary N., Dr. Prof. (correspondence)

CORPORATE SOURCE: Department of Ophthalmology and Vision Science, University of Louisville School of Medicine, Louisville, KY, United States.

AUTHOR: Foulks, Gary N., Dr. Prof. (correspondence)
CORPORATE SOURCE: 301 E. Muhammad Ali Boulevard, Louisville, KY 40202, United States.
SOURCE: Drugs and Aging, (2008) Vol. 25, No. 2, pp. 105-118.
Refs: 98
ISSN: 1170-229X CODEN: DRAGE6
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 012 Ophthalmology
017 Public Health, Social Medicine and Epidemiology
020 Gerontology and Geriatrics
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 6 Mar 2008
Last Updated on STN: 6 Mar 2008

ABSTRACT: Dry eye disease is a common and increasingly prevalent condition particularly associated with advancing age and postmenopausal women.
Epidemiological studies identify prevalence rates ranging from 7% in the US to 33% in the Asian population. Research increasingly identifies risk factors of increasing age, female sex, smoking, use of video display terminals and use of certain medications as well as environmental stresses as aggravating factors for the disease. Basic and clinical investigations provide cumulative evidence of hyperosmolarity of the tear film and ocular surface/lacrimal gland inflammation as pathogenic features of dry eye disease. A decline in systemic and local levels of sex hormones is associated with advancing age and advancing disease. Pharmacological therapeutic interventions include enhanced lubricants and anti-inflammatory drugs such as topical corticosteroids and ciclosporin (cyclosporine A). Secretagogues and hormonal supplementation are potential future therapies. The increased understanding of the contributing and pathogenetic factors responsible for dry eye provides a rationale for multiple therapeutic options for this multi-factorial disease. In the elderly patient it is important to recognize the physical and cognitive limitations that will influence the selection of appropriate topical medication.

CONTROLLED TERM: Medical Descriptors:
Asian
cataract: SI, side effect
clinical trial
cognition
*dry eye: DT, drug therapy
*dry eye: EP, epidemiology
elderly care
emulsion
environmental exposure
fluorescence
Hispanic
hormone substitution
human
inflammation
intraocular pressure
lubrication
multifactorial genetic disorder
nonhuman
osmolarity
prevalence
priority journal
review
risk factor

sex difference
side effect: SI, side effect
social behavior
staining
tear film
xerostomia: DT, drug therapy

CONTROLLED TERM: Drug Descriptors:
12 sulfodehydroabietic acid: CT, clinical trial
artificial tear: IT, drug interaction
artificial tear: DT, drug therapy
cevimeline: CT, clinical trial
cevimeline: CM, drug comparison
cevimeline: DT, drug therapy
corticosteroid: AE, adverse drug reaction
corticosteroid: DT, drug therapy
corticosteroid: PD, pharmacology
corticosteroid: TP, topical drug administration
cyclosporin A: CT, clinical trial
cyclosporin A: IT, drug interaction
cyclosporin A: DT, drug therapy
cyclosporin A: TP, topical drug administration
diquafosol: CT, clinical trial
diquafosol: DT, drug therapy
diquafosol: PD, pharmacology
diquafosol: TP, topical drug administration
duramycin: CT, clinical trial
estratest: CT, clinical trial
estratest: DT, drug therapy
estratest: TP, topical drug administration
freshkote
loteprednol etabonate: CT, clinical trial
loteprednol etabonate: DT, drug therapy
omega 3 fatty acid: DT, drug therapy
pilocarpine: CM, drug comparison
pilocarpine: DT, drug therapy
rebamipide: CT, clinical trial
rebamipide: DT, drug therapy
rebamipide: TP, topical drug administration
refresh endura
restoryl
soothe
systane

CAS REGISTRY NO.: (12 sulfodehydroabietic acid) 33159-27-2, 86408-72-2; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2; (diquafosol) 211427-08-6; (duramycin) 1391-36-2; (loteprednol etabonate) 82034-46-6; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (rebamipide) 111911-87-6

CHEMICAL NAME: (1) estratest; (2) evoxac; (3) freshkote; (4) moli 1901; (5) refresh endura; (6) restasis; (7) restoryl; (8) salagen; (9) soothe; (10) systane

COMPANY NAME: (1) Solvay (United States); (2) Daiichi Seiyaku (United States); (3) Focus (United States); (4) lantibio (United States); (5) Allergen (United States); (6) Allergen (United States); (7) Bausch and Lomb (United States); (8) MGI (United States); (9) Bausch and Lomb (United States); (10) Alcon (United States); Inspire (United States); ISTA (United States); Otsuka (United States)

reserved on STN
ACCESSION NUMBER: 2008312479 EMBASE Full-text
TITLE: Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop (2007).
AUTHOR: Pflugfelder, Stephen C., Dr. (correspondence)
CORPORATE SOURCE: Ophthalmology-Ocular Surf Ctr., Cullen Eye Institute, 6565 Fannin Street NC 205, Houston, TX 77030, United States. stevenp@bcm.tmc.edu
AUTHOR: Lemp, Michael A.
CORPORATE SOURCE: 4000 Cathedral Avenue NW, Washington, DC 20016, United States. malemp@lempdc.com
AUTHOR: Geerling, Gerd; Kinoshita, Shigero; McCulley, James; Nelson, Daniel; Novack, Gary N.; Shimazaki, Jun; Wilson, Clive
SOURCE: Ocular Surface, (Apr 2007) Vol. 5, No. 2, pp. 163-178. Refs: 185
ISSN: 1542-0124
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 012 Ophthalmology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 2008
Last Updated on STN: 10 Jul 2008

ABSTRACT: The members of the Management and Therapy Subcommittee assessed current dry eye therapies. Each member wrote a succinct evidence-based review on an assigned aspect of the topic, and the final report was written after review by and with consensus of all subcommittee members and the entire Dry Eye WorkShop membership. In addition to Its own review of the literature, the Subcommittee reviewed the Dry Eye Preferred Practice Patterns of the American Academy of Ophthalmology and the International Task Force (ITF) Delphi Panel on Dry Eye. The Subcommittee favored the approach taken by the ITF, whose recommended treatments were based on level of disease severity. The recommendations of the Subcommittee are based on a modification of the ITF severity grading scheme, and suggested treatments were chosen from a menu of therapies for which evidence of therapeutic effect had been presented.

CONTROLLED TERM: Medical Descriptors:
absence of side effects: SI, side effect
autotransplantation
blepharitis: DT, drug therapy
burning sensation: SI, side effect
clinical trial
conference paper
contact lens
dose response
drug dose comparison
drug dose increase
drug efficacy
drug formulation
drug mechanism
drug megadose
drug safety
drug tolerability

drug withdrawal
*dry eye: DT, drug therapy
*dry eye: SU, surgery
eye disease: SI, side effect
human
hyperhidrosis: SI, side effect
keratoconjunctivitis sicca: DT, drug therapy
low drug dose
monotherapy
nonhuman
osmolarity
rheumatoid arthritis: DT, drug therapy
rosacea: DT, drug therapy
salivary gland
Schirmer test
Sjoegren syndrome: DT, drug therapy
systemic disease: SI, side effect
tear film
unspecified side effect: SI, side effect

CONTROLLED TERM: Drug Descriptors:
12 sulfodehydroabietic acid: CT, clinical trial
12 sulfodehydroabietic acid: DT, drug therapy
12 sulfodehydroabietic acid: TP, topical drug administration
15 hydroxyicosatetraenoic acid: DT, drug therapy
15 hydroxyicosatetraenoic acid: PD, pharmacology
15 hydroxyicosatetraenoic acid: TP, topical drug administration
androgen: CT, clinical trial
androgen: DT, drug therapy
androgen: TP, topical drug administration
angiogenesis inhibitor: DT, drug therapy
antiinfective agent: DT, drug therapy
antiinflammatory agent: DT, drug therapy
artificial tear: CT, clinical trial
artificial tear: CB, drug combination
artificial tear: DT, drug therapy
benzalkonium chloride: TO, drug toxicity
cevimeline: AE, adverse drug reaction
cevimeline: CT, clinical trial
cevimeline: DO, drug dose
cevimeline: DT, drug therapy
cevimeline: PO, oral drug administration
corticosteroid: CT, clinical trial
corticosteroid: DT, drug therapy
cyclosporin A: AE, adverse drug reaction
cyclosporin A: CT, clinical trial
cyclosporin A: DO, drug dose
cyclosporin A: DT, drug therapy
cyclosporin A: TP, topical drug administration
de 089
diquafosol: CT, clinical trial
diquafosol: DT, drug therapy
diquafosol: TP, topical drug administration
doxycycline: CT, clinical trial
doxycycline: DO, drug dose
doxycycline: DT, drug therapy
dwelle
edetic acid: TO, drug toxicity
endura
essential fatty acid: CT, clinical trial

essential fatty acid: DT, drug therapy
fluorometholone: CT, clinical trial
fluorometholone: CB, drug combination
fluorometholone: DT, drug therapy
flurbiprofen: CT, clinical trial
flurbiprofen: CB, drug combination
flurbiprofen: DT, drug therapy
gefarnate: DT, drug therapy
gefarnate: TP, topical drug administration
genteal
hypotears: CT, clinical trial
hypotears: DT, drug therapy
hypotears: PR, pharmaceutics
hypotears pf
loteprednol etabonate: CT, clinical trial
loteprednol etabonate: DT, drug therapy
methylprednisolone: AE, adverse drug reaction
methylprednisolone: CT, clinical trial
methylprednisolone: DT, drug therapy
methylprednisolone: TP, topical drug administration
minocycline: CT, clinical trial
minocycline: DT, drug therapy
optive
pilocarpine: AE, adverse drug reaction
pilocarpine: CT, clinical trial
pilocarpine: DT, drug therapy
pilocarpine: PO, oral drug administration
placebo
rebamipide: CT, clinical trial
rebamipide: DT, drug therapy
rebamipide: PD, pharmacology
rebamipide: TP, topical drug administration
refresh
refresh free
soothe
systane
tacrolimus: CT, clinical trial
tacrolimus: DT, drug therapy
tears natural free
testosterone: CT, clinical trial
testosterone: DT, drug therapy
testosterone: TP, topical drug administration
tetracycline derivative: CT, clinical trial
tetracycline derivative: DT, drug therapy
tetracycline derivative: PD, pharmacology
tetryzoline: DT, drug therapy
theratears
unindexed drug
visine pure tears

CAS REGISTRY NO.: (12 sulfodehydroabietic acid) 33159-27-2, 86408-72-2; (15 hydroxyicosatetraenoic acid) 73180-00-4; (benzalkonium chloride) 66331-30-4, 78244-97-0, 81181-32-0; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2; (diquafosol) 211427-08-6; (doxycycline) 10592-13-9, 17086-28-1, 564-25-0; (edetic acid) 150-43-6, 60-00-4; (essential fatty acid) 11006-87-4; (fluorometholone) 426-13-1; (flurbiprofen) 5104-49-4; (gefarnate) 51-77-4; (loteprednol etabonate) 82034-46-6; (methylprednisolone) 6923-42-8, 83-43-2; (minocycline) 10118-90-8, 11006-27-2, 13614-98-7; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (

rebamipide) 111911-87-6; (tacrolimus) 104987-11-3; (testosterone) 58-22-0; (tetryzoline) 522-48-5, 84-22-0

CHEMICAL NAME: (1) de 089; (2) de 089; (3) dwelle; (4) endura; (5) genteal; (6) hypotears pf; (7) ins 365; (8) ins 365; (9) lotemax; (10) opc 12759; (11) opc 12759 ; (12) optive; (13) refresh free; (14) refresh; (15) soothe; (16) systane; (17) tears natural free; (18) theratears; (19) visine pure tears

COMPANY NAME: (1) Inspire (United States); (2) Santen (Japan); (3) Dry Eye (United States); (4) Allergan (United States); (5) Novartis (United States); (6) Novartis (United States); (7) Inspire (United States); (8) Santen (Japan); (9) Bausch and Lomb (United States); (10) Novartis (United States); (11) Otsuka (United States); (12) Allergan (United States); (13) Allergan (United States); (14) Allergan (United States); (15) Bausch and Lomb (United States); (16) Alcon (United States); (17) Alcon (United States); (18) Advanced Vision Research (United States); (19) Pfizer (United States); Senju (Japan)

```
     FILE 'HCAPLUS' ENTERED AT 17:20:22 ON 20 NOV 2009
                E US2006-566214/APPS
L1             2 SEA SPE=ON  ABB=ON  PLU=ON  US2006-566214/APPS

     FILE 'REGISTRY' ENTERED AT 17:21:52 ON 20 NOV 2009
                E 2-(4-CHLOROBENZOYLAMINO)-3-(2-QUINOLON-4-YL)PROPIONIC ACID/CN
                E 2-(4-CHLOROBENZOYLAMINO)-3-(2-QUINOLON-4-YL)PROPIONIC ACID/CN
L2             STRUCTURE UPLOADED
                D
L3             8 SEA SSS SAM L2
L4            99 SEA SSS FUL L2
L5             STRUCTURE UPLOADED
                D
L6             4 SEA SUB=L4 SSS SAM L5
L7            60 SEA SUB=L4 SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 17:36:17 ON 20 NOV 2009
L8           357 SEA SPE=ON  ABB=ON  PLU=ON  L7

     FILE 'REGISTRY' ENTERED AT 17:37:44 ON 20 NOV 2009
L9             STRUCTURE UPLOADED
                D
L10           54 SEA SUB=L7 SSS FUL L9
L11            STRUCTURE UPLOADED
                D
L12           48 SEA SUB=L7 SSS FUL L11
L13            STRUCTURE UPLOADED
                D
L14           35 SEA SUB=L7 SSS FUL L13

     FILE 'HCAPLUS' ENTERED AT 17:45:01 ON 20 NOV 2009
L15          356 SEA SPE=ON  ABB=ON  PLU=ON  L14
L16        57021 SEA SPE=ON  ABB=ON  PLU=ON  SALIVA+PFT/CT OR SALIVA?/BI
L17           11 SEA SPE=ON  ABB=ON  PLU=ON  L16(L)ACCELERATION/OBI
L18            1 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND L17
L19          630 SEA SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA+OLD,PFT/CT
L20            2 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND L19

     FILE 'REGISTRY' ENTERED AT 17:49:15 ON 20 NOV 2009
                E 4-QUINOLINEPROPANOIC ACID, A-"((4-CHLOROBENZOYL)AMINO)"
L21            1 SEA SPE=ON  ABB=ON  PLU=ON  "4-QUINOLINEPROPANOIC ACID,
                A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN

     FILE 'HCAPLUS' ENTERED AT 17:53:51 ON 20 NOV 2009
L22          353 SEA SPE=ON  ABB=ON  PLU=ON  L21
L23          112 SEA SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L24           78 SEA SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L25         1964 SEA SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L26            3 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND L16
L27            3 SEA SPE=ON  ABB=ON  PLU=ON  L18 OR L20 OR L26
L28            3 SEA SPE=ON  ABB=ON  PLU=ON  L27 AND ((L23 OR L24 OR L25))
L29            1 SEA SPE=ON  ABB=ON  PLU=ON  L23 AND L24 AND L25
L30            3 SEA SPE=ON  ABB=ON  PLU=ON  L28 OR L29

     FILE 'REGISTRY' ENTERED AT 17:57:08 ON 20 NOV 2009
                SET SMARTSELECT ON
L31             SEL PLU=ON  L21 1- NAME :       4 TERMS
                SET SMARTSELECT OFF
```

```
     FILE 'MEDLINE' ENTERED AT 17:57:08 ON 20 NOV 2009
L32          228 SEA SPE=ON  ABB=ON  PLU=ON  L31
L33          228 SEA SPE=ON  ABB=ON  PLU=ON  L21 OR L32
L34        26444 SEA SPE=ON  ABB=ON  PLU=ON  SALIVA/CT
L35         5906 SEA SPE=ON  ABB=ON  PLU=ON  ACCELERATION/CT
L36            4 SEA SPE=ON  ABB=ON  PLU=ON  L34 AND L35
L37         3041 SEA SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L38            0 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND L36 AND L37
L39            0 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND L36
L40            1 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND L37
L41            1 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND L34
L42            1 SEA SPE=ON  ABB=ON  PLU=ON  L40 OR L41
L43         8594 SEA SPE=ON  ABB=ON  PLU=ON  "SJOGREN'S SYNDROME"/CT
L44            3 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND L43
L45            3 SEA SPE=ON  ABB=ON  PLU=ON  L42 OR L44
L46           34 SEA SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L47           19 SEA SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L48          932 SEA SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L49            0 SEA SPE=ON  ABB=ON  PLU=ON  L46 AND L47 AND L48
L50            2 SEA SPE=ON  ABB=ON  PLU=ON  L45 AND ((L46 OR L47 OR L48))

     FILE 'HCAPLUS' ENTERED AT 18:08:01 ON 20 NOV 2009
L51         3703 SEA SPE=ON  ABB=ON  PLU=ON  SJOGREN SYNDROME+OLD,PFT/CT
L52            4 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND L51
L53            4 SEA SPE=ON  ABB=ON  PLU=ON  L27 OR L52

     FILE 'REGISTRY' ENTERED AT 18:10:25 ON 20 NOV 2009
                SET SMARTSELECT ON
L54             SEL PLU=ON  L21 1- NAME :       4 TERMS
                SET SMARTSELECT OFF

     FILE 'WPIX, BIOSIS' ENTERED AT 18:10:26 ON 20 NOV 2009
L55          379 SEA SPE=ON  ABB=ON  PLU=ON  L54
L56          379 SEA SPE=ON  ABB=ON  PLU=ON  L21 OR L55
L57         3824 SEA SPE=ON  ABB=ON  PLU=ON  SALIVA?(10A)(ACCEL? OR INCREAS?)
L58            0 SEA SPE=ON  ABB=ON  PLU=ON  L56 AND L57
L59            0 SEA SPE=ON  ABB=ON  PLU=ON  L56(P) L57
L60            0 SEA SPE=ON  ABB=ON  PLU=ON  L56(30A) L57
L61         4470 SEA SPE=ON  ABB=ON  PLU=ON  XEROSTO? OR DRY(3A) MOUTH?
L62            0 SEA SPE=ON  ABB=ON  PLU=ON  L56 AND L61
L63            0 SEA SPE=ON  ABB=ON  PLU=ON  L56(30A) L61
L64           82 SEA SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L65           73 SEA SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L66         3368 SEA SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L67            1 SEA SPE=ON  ABB=ON  PLU=ON  L64 AND L65 AND L66

     FILE 'REGISTRY' ENTERED AT 18:18:27 ON 20 NOV 2009
                SET SMARTSELECT ON
L68             SEL PLU=ON  L21 1- NAME :       4 TERMS
                SET SMARTSELECT OFF

     FILE 'EMBASE' ENTERED AT 18:18:28 ON 20 NOV 2009
L69          381 SEA SPE=ON  ABB=ON  PLU=ON  L68
L70          381 SEA SPE=ON  ABB=ON  PLU=ON  L21 OR L69
L71        17167 SEA SPE=ON  ABB=ON  PLU=ON  XEROSTOMIA/CT
L72         9448 SEA SPE=ON  ABB=ON  PLU=ON  SJOEGREN SYNDROME/CT
L73         7904 SEA SPE=ON  ABB=ON  PLU=ON  SALIVA/CT
L74            7 SEA SPE=ON  ABB=ON  PLU=ON  L70 AND L71
L75           12 SEA SPE=ON  ABB=ON  PLU=ON  L70 AND L72
L76            0 SEA SPE=ON  ABB=ON  PLU=ON  L70 AND L73
```

```
L77           2 SEA SPE=ON  ABB=ON  PLU=ON  L75 AND MANAGEMENT/TI
L78           5 SEA SPE=ON  ABB=ON  PLU=ON  L75 NOT (EYE OR RHEUMATOLOGIC)/TI
L79           7 SEA SPE=ON  ABB=ON  PLU=ON  L77 OR L78
L80           9 SEA SPE=ON  ABB=ON  PLU=ON  L74 OR L79
L81          35 SEA SPE=ON  ABB=ON  PLU=ON  NAGAMOTO H?/AU
L82          15 SEA SPE=ON  ABB=ON  PLU=ON  KOHASHI M?/AU
L83         863 SEA SPE=ON  ABB=ON  PLU=ON  OKA H?/AU
L84           0 SEA SPE=ON  ABB=ON  PLU=ON  L81 AND L82 AND L83
L85           2 SEA SPE=ON  ABB=ON  PLU=ON  L80 AND (L81 OR L82 OR L83)

     FILE 'REGISTRY' ENTERED AT 18:31:38 ON 20 NOV 2009

     FILE 'HCAPLUS' ENTERED AT 18:31:46 ON 20 NOV 2009
               D STAT QUE L30

     FILE 'MEDLINE' ENTERED AT 18:32:00 ON 20 NOV 2009
               D STAT QUE L50

     FILE 'WPIX, BIOSIS' ENTERED AT 18:32:54 ON 20 NOV 2009
               D STAT QUE L67

     FILE 'EMBASE' ENTERED AT 18:33:02 ON 20 NOV 2009
               D STAT QUE L85

     FILE 'HCAPLUS, MEDLINE, WPIX, EMBASE' ENTERED AT 18:33:28 ON 20 NOV 2009
L86           3 DUP REMOVE L30 L50 L67 L85 (5 DUPLICATES REMOVED)
                    ANSWERS '1-3' FROM FILE HCAPLUS
               D L86 IBIB ABS HITSTR 1-3

     FILE 'HCAPLUS' ENTERED AT 18:33:53 ON 20 NOV 2009
               D STAT QUE L53

     FILE 'MEDLINE' ENTERED AT 18:34:11 ON 20 NOV 2009

     FILE 'HCAPLUS' ENTERED AT 18:34:19 ON 20 NOV 2009
L87           1 SEA SPE=ON  ABB=ON  PLU=ON  L53 NOT L30

     FILE 'MEDLINE' ENTERED AT 18:34:42 ON 20 NOV 2009
               D STAT QUE L45
L88           1 SEA SPE=ON  ABB=ON  PLU=ON  L45 NOT L50

     FILE 'WPIX, BIOSIS' ENTERED AT 18:35:23 ON 20 NOV 2009
               D STAT QUE L60
               D STAT QUE L62

     FILE 'EMBASE' ENTERED AT 18:35:44 ON 20 NOV 2009
               D STAT QUE L80
L89           7 SEA SPE=ON  ABB=ON  PLU=ON  L80 NOT L85

     FILE 'HCAPLUS, MEDLINE, EMBASE' ENTERED AT 18:36:18 ON 20 NOV 2009
L90           8 DUP REMOVE L87 L88 L89 (1 DUPLICATE REMOVED)
                    ANSWER '1' FROM FILE HCAPLUS
                    ANSWER '2' FROM FILE MEDLINE
                    ANSWERS '3-8' FROM FILE EMBASE



=>
```

Uploading L2.str



chain nodes :
11 12 13 14 15 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21
chain bonds :
8-13 10-11 11-12 12-14 14-15 15-16 15-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-13 9-10 10-11 11-12 12-14
14-15 15-16 15-22 16-17 16-21 17-18 18-19 19-20 20-21

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS

Uploading L5.str




```
chain nodes :
11  12  13  14  15  22  23  24  25  26
ring nodes :
1  2  3  4  5  6  7  8  9  10  16  17  18  19  20  21
chain bonds :
8-13  10-11  11-12  12-14  12-23  14-15  15-16  15-22  19-26  23-24  23-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  16-17  16-21  17-18  18-19
19-20  20-21
exact/norm bonds :
5-7  6-10  7-8  8-9  8-13  9-10  12-14  14-15  15-22  23-24  23-25
exact bonds :
10-11  11-12  12-23  15-16  19-26
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom
22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS
```

Uploading L13.str




```
chain nodes :
11  12  13  14  15  22  23  24  25  26
ring nodes :
1  2  3  4  5  6  7  8  9  10  16  17  18  19  20  21
chain bonds :
8-13  10-11  11-12  12-14  12-23  14-15  15-16  15-22  19-26  23-24  23-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  16-17  16-21  17-18  18-19
19-20  20-21
exact/norm bonds :
5-7  6-10  7-8  8-9  8-13  9-10  12-14  14-15  15-22
exact bonds :
10-11  11-12  12-23  15-16  19-26
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21  23-24  23-25


Connectivity :
```

```
12:3 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom
22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS
```